|1.||Hedley, Douglas: 1 article (05/2007)|
|2.||Scanlon, Ian: 1 article (05/2007)|
|3.||Friedlos, Frank: 1 article (05/2007)|
|4.||Chen, Ping: 1 article (05/2007)|
|5.||Ogilvie, Lesley M: 1 article (05/2007)|
|6.||Marais, Richard: 1 article (05/2007)|
|7.||Martin, Janet: 1 article (05/2007)|
|8.||Schepelmann, Silke: 1 article (05/2007)|
|9.||Springer, Caroline J: 1 article (05/2007)|
|10.||Chester, Kerry A: 1 article (01/2005)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
05/15/2007 - "Following delivery of the vector (AdV.hTERT-CPG2) and expression of CPG2 in cancer cells, the prodrug ZD2767P was administered for conversion by CPG2 to a cytotoxic drug. "
07/15/1996 - "Administration of the ZD2767 conjugate to nude mice bearing LoVo colorectal xenografts resulted in approximately 1% of injected ZD2767 conjugate localizing/g of tumor after 72 h, and blood and normal tissue levels of the conjugate were 10-50-fold lower. "
07/15/1996 - "ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/01/2002 - "The prodrug 4-[N,N-bis(2-iodoethyl)amino]phenoxycarbonyl L-glutamic acid (ZD2767P)+activating enzyme carboxypeptidase G2 (CPG2) displayed growth inhibitory activity (IC(50) 0.04-2.2 microM) in colorectal tumour and non-small cell lung cancer (NSCLC) cell lines, and was more potent than a monofunctional ZD2767D analogue (colorectal cell lines-IC(50) 18-38 microM), synthesized for the first time. "
|1.||Glutamic Acid (Glutamate)
|2.||gamma-Glutamyl Hydrolase (Carboxypeptidase G2)
|1.||Heterologous Transplantation (Xenotransplantation)